期刊
PROSTATE CANCER AND PROSTATIC DISEASES
卷 26, 期 1, 页码 151-155出版社
SPRINGERNATURE
DOI: 10.1038/s41391-022-00585-8
关键词
-
In patients with biochemical recurrence after radical prostatectomy, the progression to castration-resistant prostate cancer (CRPC) may serve as a potential intermediate endpoint for developing metastatic disease. Based on the study results, there is a high correlation between CRPC-free survival (CRPC-FS) and metastasis-free survival (MFS), suggesting that CRPC-FS could potentially be used as an intermediate endpoint in trials for patients with biochemical recurrence initiating androgen deprivation therapy.
Purpose Metastasis-free survival (MFS) is a surrogate for overall survival (OS) in men with non-metastatic castration-resistant prostate cancer (CRPC), but this endpoint may take years to develop in men with non-metastatic castrate-sensitive disease. The study objective was to examine whether progression to CRPC is a potential intermediate endpoint for developing metastatic disease in patients with biochemical recurrence (BCR) after radical prostatectomy (RP). Materials and methods Men with BCR following RP who had PSA doubling times (PSADT) < 9 months and no metastasis at the time of initiating androgen deprivation therapy (ADT) (n = 210) were included. The primary objective was to assess the correlation between CRPC-free survival (CRPC-FS) and MFS, and the secondary objective was to assess the correlation between time to metastasis and time to CRPC. Kendall's Tau was used to test the correlation for the primary and secondary outcomes. Results The median MFS was 104 months (95% CI: 83-114) and median CRPC-FS was 100 months (95% CI: 80-114). Based on the Kaplan-Meier curve, the greatest difference in time to MFS and CRPC-FS was around 70% free survival, which was reached at 61.2 months for MFS and 49.6 months for CRPC-FS. Kendall's Tau for the correlation between CRPC-FS and MFS and between time to CRPC and time to metastasis was 0.867 (95% CI: 0.765-0.968) and 0.764 (95% CI: 0.644-0.884), respectively. Conclusions Given the high correlation between CRPC-FS and MFS, after validation, CRPC-FS may serve as a potential intermediate endpoint in trials for men with BCR initiating ADT following local therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据